BRPI0418330A - composições sólidas de drogas de solubilidade baixa e poloxámeros - Google Patents

composições sólidas de drogas de solubilidade baixa e poloxámeros

Info

Publication number
BRPI0418330A
BRPI0418330A BRPI0418330-4A BRPI0418330A BRPI0418330A BR PI0418330 A BRPI0418330 A BR PI0418330A BR PI0418330 A BRPI0418330 A BR PI0418330A BR PI0418330 A BRPI0418330 A BR PI0418330A
Authority
BR
Brazil
Prior art keywords
poloxamers
low solubility
solid compositions
solubility drugs
drugs
Prior art date
Application number
BRPI0418330-4A
Other languages
English (en)
Inventor
Daniel Tod Smithey
Warren Kenyon Miller
Dwayne Thomas Friesen
Walter Christian Babcock
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0418330A publication Critical patent/BRPI0418330A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçõES SóLIDAS DE DROGAS DE SOLUBILIDADE DE BAIXA E POLOXáMEROS. A presente invenção refere-se as descritas composições sólidas de drogas de baixa solubilidade e poloxâmeros que provêem aumento de concentração quando administrados a um ambiente de uso aquoso.
BRPI0418330-4A 2003-12-31 2004-12-20 composições sólidas de drogas de solubilidade baixa e poloxámeros BRPI0418330A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53383603P 2003-12-31 2003-12-31
PCT/IB2004/004287 WO2005065657A2 (en) 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers

Publications (1)

Publication Number Publication Date
BRPI0418330A true BRPI0418330A (pt) 2007-05-02

Family

ID=34748969

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418330-4A BRPI0418330A (pt) 2003-12-31 2004-12-20 composições sólidas de drogas de solubilidade baixa e poloxámeros

Country Status (6)

Country Link
US (1) US8974823B2 (pt)
EP (1) EP1701704A2 (pt)
JP (1) JP2007517016A (pt)
BR (1) BRPI0418330A (pt)
CA (1) CA2548376A1 (pt)
WO (1) WO2005065657A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP2142178B1 (en) * 2007-03-29 2012-01-11 F. Hoffmann-La Roche AG Pharmaceutical composition and process
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
SMT202000390T1 (it) * 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
JP2014532658A (ja) * 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CN111700878A (zh) * 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
JP5946798B2 (ja) * 2013-06-18 2016-07-06 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
JP5934677B2 (ja) * 2013-06-18 2016-06-15 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP6010060B2 (ja) * 2014-02-21 2016-10-19 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
RU2639819C2 (ru) * 2014-12-30 2017-12-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Композиция, ингибирующая теломеразу
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
DK0996429T3 (da) 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
AU4797999A (en) 1998-07-22 2000-02-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble nsaids
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
WO2001034118A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Solid dispersion pharmaceutical formulations
JP2004500358A (ja) 1999-12-08 2004-01-08 ファルマシア　コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
KR100806412B1 (ko) 2000-01-28 2008-02-21 스미스클라인 비참 코포레이션 전기방사 약제학적 조성물
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
PE20011184A1 (es) * 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US20010036959A1 (en) 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0015239D0 (en) 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
DE10038571A1 (de) 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
KR20020014570A (ko) 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
CZ20033211A3 (cs) * 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AU2003214387A1 (en) * 2002-03-07 2003-09-16 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers

Also Published As

Publication number Publication date
WO2005065657A3 (en) 2006-06-22
CA2548376A1 (en) 2005-07-21
US20070141143A1 (en) 2007-06-21
JP2007517016A (ja) 2007-06-28
US8974823B2 (en) 2015-03-10
WO2005065657A2 (en) 2005-07-21
EP1701704A2 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
HN2002000152A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
ECSP034913A (es) Composiciones farmacéuticas que comprenden fármacos de solubilidad baja y/o sensibles a ácidos, y polimeros ácidos neutralizados
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
BRPI0411528A (pt) uso de isomalte como prebiótico
UY31736A (es) Derivados sustituidos de pirazol y su uso
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
BR0308613A (pt) Combinação de compostos orgânicos
HN2002000300A (es) Nuevos derivados de piperazina
GT200900082A (es) Composiciones de fenilalquilamino-carbamato
EA200700312A1 (ru) Композиции для доставки лекарственных средств с высокой водорастворимостью
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
CR9495A (es) Composicion en emulsion estable
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
BRPI0418474A (pt) solução aquosa parenteral estável
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
PA8684501A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
BRPI0620229A8 (pt) formulação
ECSP066912A (es) Formulaciones de dispersiones sólidas de acetato de bazedoxifeno
HN2004000526A (es) Hormonas de administracion transdermica que no necesitan potenciadores de penetracion
BRPI0409330A (pt) eliminador de oxigênio ativo derivado de substáncia natural e seu uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.